Fate Therapeutics Inc (FATE) concluded trading on Thursday at a closing price of $1.79, with 4.23 million shares of worth about $7.57 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -43.35% during that period and on Thursday the price saw a gain of about 8.48%. Currently the company’s common shares owned by public are about 113.88M shares, out of which, 97.96M shares are available for trading.
Stock saw a price change of 7.83% in past 5 days and over the past one month there was a price change of -39.53%. Year-to-date (YTD), FATE shares are showing a performance of 8.48% which decreased to -51.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.55 but also hit the highest price of $8.83 during that period. The average intraday trading volume for Fate Therapeutics Inc shares is 2.84 million. The stock is currently trading -8.30% below its 20-day simple moving average (SMA20), while that difference is down -22.89% for SMA50 and it goes to -51.93% lower than SMA200.
Fate Therapeutics Inc (NASDAQ: FATE) currently have 113.88M outstanding shares and institutions hold larger chunk of about 89.18% of that.
The stock has a current market capitalization of $203.88M and its 3Y-monthly beta is at 2.02. It has posted earnings per share of -$1.65 in the same period. It has Quick Ratio of 8.29 while making debt-to-equity ratio of 0.27. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FATE, volatility over the week remained 8.43% while standing at 10.58% over the month.
Stock’s fiscal year EPS is expected to rise by 0.38% while it is estimated to decrease by -2.26% in next year.
Coverage by Piper Sandler stated Fate Therapeutics Inc (FATE) stock as an Overweight in their note to investors on June 17, 2024, suggesting a price target of $6 for the stock. On March 27, 2023, Wells Fargo Resumed their recommendations, while on January 24, 2023, H.C. Wainwright Downgrade their ratings for the stock with a price target of $7. Stock get a Neutral rating from Wedbush on January 06, 2023.
